Please Wait
Applying Filters...
menu
    • menu
    Seqens is an integrated global leader in pharmaceutical solutions & specialty ingredients & provides custom-made solutions.

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    EUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

    Virtual Booth

    Contact Supplier

    ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Menu

    Dovitinib

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    PLOS ONE Publishes Data on Allarity DRP® Companion Diagnostic for Dovitinib
    PLOS ONE Publishes Data on Allarity DRP® Companion Diagnostic for Dovitinib

    30 Aug 2023

    // GLOBENEWSWIRE

    https://www.globenewswire.com//news-release/2023/08/30/2734776/0/en/PLOS-ONE-Publishes-Data-on-Allarity-Therapeutics-DRP-Companion-Diagnostic-for-Dovitinib.html

    GLOBENEWSWIRE
    30 Aug 2023
    Share Share
    Allarity Doses First Patient in Ph1b Trial Evaluating Dovitinib and Stenoparib
    Allarity Doses First Patient in Ph1b Trial Evaluating Dovitinib and Stenoparib

    20 Mar 2023

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2023/03/20/2630044/0/en/Allarity-Therapeutics-Doses-First-Patient-in-Phase-1b-Clinical-Trial-Evaluating-Dovitinib-and-Stenoparib-Combination-in-Advanced-Solid-Tumors.html

    GLOBENEWSWIRE
    20 Mar 2023
    Share Share
    FDA sinks Allarity’s plans for lead oncology asset
    FDA sinks Allarity’s plans for lead oncology asset

    03 Aug 2022

    // Gabrielle Masson FIERCEBIOTECH

    https://www.fiercebiotech.com/biotech/forced-clarity-allarity-loses-hope-lead-asset-restructures-pipeline-after-fda-meeting

    Gabrielle Masson FIERCEBIOTECH
    03 Aug 2022
    Share Share
    Allarity Therapeutics partners with Lonza to manufacture Dovitinib
    Allarity Therapeutics partners with Lonza to manufacture Dovitinib

    23 Sep 2021

    // PHARMAFILE

    http://www.pharmafile.com/news/588506/allarity-therapeutics-partners-lonza-manufacture-dovitinib

    PHARMAFILE
    23 Sep 2021
    Share Share
    Allarity Presents Dovitinib Survival Data from DRP® Screened RCC Patients
    Allarity Presents Dovitinib Survival Data from DRP® Screened RCC Patients

    16 Sep 2021

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2021/09/16/2298130/0/en/Allarity-Therapeutics-Presents-Dovitinib-Survival-Data-from-DRP-Screened-RCC-Patients-at-ESMO-2021-Virtual-Congress.html

    GLOBENEWSWIRE
    16 Sep 2021
    Share Share
    Allarity Therapeutics Receives Acceptance & Review Notification From USFDA
    Allarity Therapeutics Receives Acceptance & Review Notification From USFDA

    05 Jul 2021

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2021/07/05/2257841/0/en/Allarity-Therapeutics-Receives-Acceptance-Review-Notification-from-U-S-FDA-for-Pre-Market-Approval-Application-for-Dovitinib-DRP.html

    GLOBENEWSWIRE
    05 Jul 2021
    Share Share